{"id":"comparator-valdecoxib","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Cardiovascular events"}]},"_chembl":{"chemblId":"CHEMBL865","moleculeType":"Small molecule","molecularWeight":"314.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a selective COX-2 inhibitor, valdecoxib preferentially blocks COX-2 enzyme activity over COX-1, thereby reducing inflammatory prostaglandins while theoretically sparing the protective prostaglandins produced by COX-1 in the gastrointestinal tract and platelets. This selectivity was intended to provide anti-inflammatory and analgesic benefits with a reduced risk of gastrointestinal ulceration compared to non-selective NSAIDs.","oneSentence":"Valdecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:19.702Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoarthritis"},{"name":"Rheumatoid arthritis"},{"name":"Acute pain"},{"name":"Dysmenorrhea"}]},"trialDetails":[{"nctId":"NCT00285649","phase":"NA","title":"Predicting Patients' Response to Spinal Manipulation","status":"COMPLETED","sponsor":"Palmer College of Chiropractic","startDate":"2004-07","conditions":"Low Back Pain","enrollment":192},{"nctId":"NCT00092339","phase":"PHASE3","title":"A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-08-01","conditions":"Postoperative Pain","enrollment":125},{"nctId":"NCT00092300","phase":"PHASE3","title":"A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-05","conditions":"Postoperative Pain","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":211,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Comparator: valdecoxib","genericName":"Comparator: valdecoxib","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valdecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain. Used for Osteoarthritis, Rheumatoid arthritis, Acute pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}